NP/PA Connect
News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
Publication
Dermatology Times
More
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
    • Biologic Treatments for Moderate to Severe Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
    • Emerging Therapies Plaque Psoriasis
    • Treatments for Plaque Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Skin Cancer (Nonmelanoma)
  • Vitiligo
  • Wound Care
Spotlight -
Derm NP/PA Connect
Advertisement

Nick Loftin

Advertisement

Articles by Nick Loftin

5 steps to make telehealth work for physicians and patients

ByNick Loftin
March 8th 2022

There are barriers to telehealth adoption that physicians must overcome to realize the technology’s promise.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Dermatology Times

    1

    Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications

    2

    Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib

    3

    Auricular Acupuncture for Facial Rejuvenation: Results from a Large Real-World Clinical Series

    4

    Off-Label Case Series: Topical Roflumilast for Mild HS

    5

    Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials

    • About
    • Advertise
    • Contact Us
    • Job Board
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy Policy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us